SBIR/STTR Research Award

Long-Acting G-CSF Analog for Treating ARS

Award identifier a65a0cac0b1898b2cd56745444f807c57d52cbc1a3b089dfc3a91fd4d36ac661Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$498,196

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Brain Biosciences, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
PFWBBNMA5LN7
Solicitation number
PA12-088
Topic code
NIMH

Research abstract

DESCRIPTION (provided by applicant): Neurodegenerative diseases, such as Alzheimer and other dementias, present significant societal and economic burden. The number of patients suffering from these disorders grows rapidly owing to the aging of the world population. Alzheimer's Association projects that the number of Americans living with Alzheimer's disease (AD) will increase from 5.4M today to 16 M in 2050. Management and treatment of brain disorders is a critical task facing the healthcare innovation system; continuing progress in this field will depend on early, high-confidence diagnosis. Amyloid imaging agents, the new promising class of Positron Emission Tomography (PET) radiopharmaceuticals, enable diagnosis of Alzheimer's pathology at the early stagesof disease. Brain Biosciences seeks to make neurological PET imaging affordable and widely available both in the clinic and in the research laboratory. To achieve this goal we aim to develop, validate, and obtain 510(k) FDA clearance for CerePET , a compact, portable, high-performance, and cost- effective, PET scanner for brain imaging. This innovative device is designed to achieve high resolution at a fraction of the cost of currently marketed whole body PET systems. CerePET applications include: (i) evaluation of amyloid burden in patients with suspected Alzheimer disease, mild cognitive impairment, and other neurodegenerative disorders, (ii) multicenter clinical trials of CNS-targeted pharmaceuticals using PET scan as a biomarker, (iii) clinical neuroscience research. During this Fast-track SBIR project, CerePET will be rigorously validated using a set of internationally recognized tests. CerePET imaging performance will be characterized per NEMA NU2-2007; the scanner will be used in a clinical study comparing amyloid burden in patients with Alzheimer's disease and healthy controls. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This application proposes to develop small-footprint, high performance Positron Emission Tomography (PET) scanneroptimized for brain imaging. This device will lower the cost and increase availability of neurological PET examinations both in the clinical and research settings.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2013–2015). Reported award amounts total $3,591,615. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.